Non-Muscle Invasive Urothelial Carcinoma
Advertisement
The study’s major efficacy outcomes included a complete response in 78% of patients.
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
Drs. Galsky and Tawagi detail the event-free survival subgroup analyses based on disease stage from the CREST study.
Updated CREST trial explores sasanlimab plus BCG in BCG-naive, high-risk NMIBC, with new insights by disease stage and tumor.
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Adding one year of treatment with durvalumab to BCG can extend the time that patients live without disease recurrence.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.